Skip to content

Brazilian inteRvention to Increase eviDence usaGe in practicE - Cardiovascular Prevention

A Cluster Randomized Trial Evaluating the Effect of a Multifaceted Intervention to Increase Evidence Based Strategies Usage for Cardiovascular Prevention.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02851732
Acronym
BRIDGE-CV
Enrollment
1623
Registered
2016-08-02
Start date
2016-08-26
Completion date
2018-09-30
Last updated
2018-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases

Keywords

Quality Improvement, Cluster Analysis

Brief summary

The purpose of the study is assess the impact of a multifaceted quality improvement intervention in adherence to evidence based therapies prescription (according to local guidelines) for cardiovascular prevention in high risk patients in 12 months.

Detailed description

The quality improvement strategy being assessed in this study will be applied to the healthcare team, thus any intervention that is not well established in the literature will not be prescribed to the patients. Thus, this trial does not imply any additional risk for patients. Furthermore, if this strategy is proved to be effective, it may be offered as a new clinical practice that might benefit brazilian patients. BRIDGE-CV consists of a quality improvement project by the incorporation of evidence based interventions in public and private hospitals in Brazil. The chosen setting is cardiovascular prevention in high risk patients since cardiovascular diseases represent the major cause of death in Brazil. It will be developed a cluster randomized trial, where hospitals will be allocated to receive or not the multifaceted intervention. The patients will be followed for 12 months in order to assess if the multifaceted intervention can increase the evidence based prescriptions. If this is the case, this tool package may be offered as a quality improvement intervention for all hospitals. Sites will be selected through the HCor investigators network. Invited sites must complete a screening form in order to verify eligibility and feasibility of application of the BRIDGE CV tools.Clusters will be randomized and allocated 1:1 to the Multifaceted Intervention Group or to the Control Group. Once the hospital/center is allocated to one of the groups every patient at that institution must be assisted following the same procedures. The randomization list will be created considering a random function with equal probability of being allocated to each of the groups. Each site will receive a code number and just this numbers will be used during randomization. This procedure will be performed by the HCor statistician ensuring allocation concealment. The study coordinator will inform the site what procedures must be taken, without revealing to the statistician which hospitals are allocated to the intervention group. The sample will be stratified considering primary care centers and secondary/tertiary outpatients' clinics. Considering the open nature of the study, treatment allocation will not be blinded to the investigators, health care providers and patients. However, clinical outcomes will be assessed and validated by a blinded committee.

Interventions

The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports

Sponsors

Amgen
CollaboratorINDUSTRY
Hospital do Coracao
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 40 years old, with manifested atherothrombotic diseases ( coronary artery disease, stroke or transient ischemic attack, or peripheral artery disease)

Exclusion criteria

* Patients from institutions that don't provide the Institutional Authorization Term, as well as patients that withdraw Inform Consent for Data Collection. * Patients with a history of atrial fibrillation or that at the discretion of the physician needs anticoagulation, will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Adherence to evidence based therapies12 monthsAdherence to evidence based therapies ( aspirin/antiplatelets , lipid lowering agents(statins) and ACE inhibitors/ARB) in an all or none model for patients without contra indication in a period of 12 months.

Secondary

MeasureTime frameDescription
LDL < 100mg/dL in 12 months12 monthsPercentage of eligible patients with LDL \< 100mg/dL
LDL < 70mg/dL in 12 months12 monthsPercentage of eligible patients with LDL \< 70mg/dL
Adherence to Lipid Lowering Agents (Statins)12 monthsAdherence to Lipid Lowering Agents (Statins) in patients without contraindications
Adherence to Antiplatelets12 monthsAdherence to Antiplatelets in Patients without contra-indications
Adherence to ACE inhibitors or ARBs12 MonthsAdherence to ACE inhibitors or ARBs in patients without contra-indications
Adherence to evidence based therapiessix and twelve monthsAdherence to aspirin/antiplatelets, lipid lowering agents(statins) and ACE Inhibitors/ARB in patients without contra indications (All or None Model).
Adherence to Beta Blockers12 monthsAdherence to Beta Blockers in patients with a history of myocardial infarction and without contra-indications
Smoke Cessation Education12 MonthsSmoke Cessation Education delivered to smokers
Blood Pressure < 140 x 90 mmHg12 monthsPercentage of patients with blood pressure \< 140 x 90 mmHg
Blood Pressure < 120 mmHg12 monthsPercentage of patients with blood pressure \< 140 x 90 mmHg
Composite Outcome of Major Cardiovascular Events12 monthsComposite Outcome (death, non fatal myocardial infarction and non fatal stroke)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026